Applications

Home / Applications
Applications

HealthTell provides insights to many different types of biomolecular interactions. The Rational Discovery program uses a broad range of diverse, proprietary, and customized chemical libraries to characterize antibodies and derivatives, from any source. Use of these unique insights conferred by analysis of binding leads to discovery and qualifification of mAb lead candidates at accelerated timelines, reduced economics, and improved outcomes.

HealthTell uses its diverse chemical libraries to characterize humoral immune system activity and memory by identification of ImmunoSignatures™. These signatures, binding events from biological samples, including circulating antibodies and circulating antibody derivatives are made possible from any individual’s specimen sample. HealthTell serves as the world-leading Immunomics pillar for the Digital Life Alliance.

 

Rational Discovery

HealthTell offers the Biopharmaceutical Industry mAb service to solve costly and time consuming issues identifying lead therapeutic candidates by revealing highly informative content not possible in today’s process technologies on the market. Our solution is specific, reproducible, and affordable.


We work with biotherapeutic innovators to drive discovery programs that :

  • Maintain Specificity through optimization and developability.
  • Ensure Pan-Species Reactivity
  • Reveal undetectable rare functional clones
  • Eliminate parasitic clones
  • Avoid dominant epitopes

Antibodies remain the principal messenger molecules controlling immune response and protecting us from disease. Monoclonal Antibody Drugs (Biologics) now represent over 50%  of all drugs in development and are projected to grow rapidly in next 10 years.   In May, 2017 Downing et.al. verified that biologics are nearly 2x as likely to be subject to post-market safety events than other drugs. In today’s market, the ability to design and engineer antibodies is limited, due to reliance on poor tools that lack a precise and broad view of critical binding events. Analytical methods do not provide clear resolution to off-target binding, which will lead to decreased adverse events and sufficient information to claim IP. It is increasingly evident that sub-optimal target binding and limited specificity substantially constrain biotherapeutic research and development productivity.

HealthTell provides a simple process to bin & map antibodies in a single experiment, resulting in high resolution insight to binding sequences. We know precisely where every amino acid is located on a peptide sequence. This eliminates the laborious steps required today to bin by cross blocking and subsequently map by utilizing, for example, Xray Crystolography (most often multiple methods are utilized: Mass-Spec, mutagenesis and display methods).

Our technology can be utilized early in the discovery process or once a panel of clones are identified and will yield better candidates by informing on/off target binding, linear, and conformational epitopes. Our expert team are capable of designing proprietary immunogens to steer to desired epitopes.

Rational Discovery

HealthTell offers the Biopharmaceutical Industry mAb service to solve costly and time consuming issues identifying lead therapeutic candidates by revealing highly informative content not possible in today’s process technologies on the market. Our solution is specific, reproducible, and affordable.


We work with biotherapeutic innovators to drive discovery programs that :

  • Maintain Specificity through optimization and developability.
  • Ensure Pan-Species Reactivity
  • Reveal undetectable rare functional clones
  • Eliminate parasitic clones
  • Avoid dominant epitopes

Antibodies remain the principal messenger molecules controlling immune response and protecting us from disease. Monoclonal Antibody Drugs (Biologics) now represent over 50%  of all drugs in development and are projected to grow rapidly in next 10 years.   In May, 2017 Downing et.al. verified that biologics are nearly 2x as likely to be subject to post-market safety events than other drugs. In today’s market, the ability to design and engineer antibodies is limited, due to reliance on poor tools that lack a precise and broad view of critical binding events. Analytical methods do not provide clear resolution to off-target binding, which will lead to decreased adverse events and sufficient information to claim IP. It is increasingly evident that sub-optimal target binding and limited specificity substantially constrain biotherapeutic research and development productivity.

HealthTell provides a simple process to bin & map antibodies in a single experiment, resulting in high resolution insight to binding sequences. We know precisely where every amino acid is located on a peptide sequence. This eliminates the laborious steps required today to bin by cross blocking and subsequently map by utilizing, for example, Xray Crystolography (most often multiple methods are utilized: Mass-Spec, mutagenesis and display methods).

Our technology can be utilized early in the discovery process or once a panel of clones are identified and will yield better candidates by informing on/off target binding, linear, and conformational epitopes. Our expert team are capable of designing proprietary immunogens to steer to desired epitopes.

ImmunoSignature

Researchers have been attempting to develop noninvasive, blood-based clinical diagnostics for over 100 years. Remarkably, less than 30 new biomarkers have been approved since that time. The vast majority of these testes are relatively nonspecific or insensitive and few are effective early markers. In addition, there is growing concern that regular screening with these biomarkers may do more harm than good, since the large number of false positives translates to unnecessary therapeutic interventions that carry increased risk to the patient and increased cost to the healthcare system.

Any disease that affects the immune response(autoimmune, cancer, infectious disease, metabolic and neurologic diseases) can potentially be measured using immune signature Test. The basis for this unique platform is high-density peptide array that is specially designed to query the myriad of antibodies present in a human blood sample. The fabrication of theses arrays leverages and processes similar to those used in the manufacturing of silicon-based electronics, making it scalable. Additional indications do not require a new product development process rather a new algorithm.

HealthTell’s ImmunoSignature adds value to the Clinical development process and identification of diseases in the general population. Multiple diseases are under review with partners in academia and biopharmaceuticals to assess the impact of patient stratification, patient responders and incidence of adverse events among patients.

Notable demonstration of differential disease detection is evidenced among patients with autoimmune diseases: lupus, dermatomyositis, scleroderma and rheumatoid arthritis as published at ACR, 2016. Evaluation of the ImmunoSignature suggests distinction among patients with varying disease activity for Lupus. Studies reflect our technology can identify responders and non-responders as well as adverse events. This is particularly helpful to pharmaceutical firms seeking more insight into clinical studies.

Personalized Health

In January, 2017, HealthTell became the Immunomics member of Digital Life Alliance, an artificial intelligence (AI) based health care platform. Founded by Shenzhen-based iCarbonX. The vision is to build an ecosystem to monitor health by measuring an individual’s biology, psychology, and personal behavior. The first intelligent digital guide will be created, through artificial intelligence data mining which combines biologics: immunomics (HealthTell), metabolomics, genomics, proteomics, trascriptomics, and patient reported outcomes. The goal is to provide a personalized health management system which presents recommendations for a healthier lifestyle.